Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-life effectiveness in asthma of Symbicort Single Inhaler Therapy (RELEASE)
2005-000372-41Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Apr 2005
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of budesonide in asthma (2 arms), sponsored by AstraZeneca. Primary endpoints: Change in ACQ score from baseline to average of visits 3–5 and Change in ACQ score from baseline to 4 weeks. Started Apr 2005; status: completed.
02
Drugs
budesonide
03
Conditions
asthma
Beyond the preview
Go deeper on 2005-000372-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000372-41.